Patients can “Outnumber PAH” by developing a strong support team, advises an unbranded educational campaign launched by Merck against pulmonary arterial hypertension (PAH), a rare, progressive disease ...
Please provide your email address to receive an email when new articles are posted on . Researchers have developed an automated algorithm that can calculate a patient’s virtual echocardiography ...
Active ingredient: Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg; tabs. Indication: Treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback